Class Action Filed Against Cytokinetics Over Alleged NDA Timeline Misrepresentation
A class action lawsuit has been filed against Cytokinetics, Inc. (NASDAQ: CYTK) for allegedly providing false information about the timeline for the New Drug Application (NDA) submission and approval process for aficamten. The lawsuit, filed in November 2025, accuses the company of misleading investors in the stock market.
The Rosen Law Firm has reminded purchasers of Cytokinetics common stock between December 27, 2023 and May 6, 2025 of a November 17, 2025 deadline to serve as lead plaintiff in the case. The lawsuit alleges that defendants represented that Cytokinetics expected FDA approval for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date. However, it is claimed that the company failed to disclose material risks, including its failure to submit a Risk Evaluation and Mitigation Strategy (REMS) that could delay the regulatory process.
Purchasers of Cytokinetics common stock during the Class Period may be entitled to compensation through a contingency fee arrangement, without any out-of-pocket fees or costs.
The lawsuit against Cytokinetics, Inc. is ongoing, with a lead plaintiff deadline having passed. Investors who purchased the company's stock during the specified period may be eligible for compensation. The outcome of the case will likely impact the company's future operations and investor relations in the stock market.
